Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases
Authors: Yang-Si Li, Mei-Mei Zheng, Ben-Yuan Jiang, Hai-Yan Tu, Jin-Ji Yang, Xu-Chao Zhang, Yi-Long Wu
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Owing to the improvement of systemic therapies for lung cancer, patients live longer, but the incidence of central nervous system (CNS) metastases also increases. Cerebrospinal fluid (CSF) has been proven better than plasma to reveal unique genetic profiling of intracranial metastases. How genetic alterations in CSF are associated with the prognosis of this heterogeneous patient group remains elusive. <h3>Objective</h3> To examine the association of molecular alterations in CSF with the survival of patients with a diagnosis of lung adenocarcinoma and CNS metastases. <h3>Design, Setting, and Participants</h3> This retrospective cohort analysis of 94 patients with advanced lung adenocarcinoma and CNS metastases was conducted from July 1, 2016, to July 31, 2018. Patients' CSF samples were collected, and next-generation sequencing of CSF circulating tumor DNA was performed. <h3>Main Outcome and Measures</h3> The main outcome was survival after diagnosis with CNS metastases. Genotyping of CSF circulating tumor DNA was studied to examine its association with the clinical outcomes of patients with CNS metastases. <h3>Results</h3> Of the 94 patients (49 male; mean [SD] age, 53 [1] years) with lung adenocarcinoma and CNS metastases evaluated, 79 harbored an<i>EGFR</i>variant. The most common genes seen in CSF were<i>EGFR</i>(79 [84.0%]),<i>TP53</i>(57 [60.6%]),<i>MET</i>(23 [24.5%]),<i>CDKN2A</i>(22 [23.4%]),<i>MYC</i>(20 [21.3%]),<i>NTRK1</i>(19 [20.2%]), and<i>CDK6</i>(15 [16.0%]). Cluster analysis identified 5 molecular subtypes of CNS metastases. Patients in cluster I had the shortest median survival after diagnosis of CNS metastases compared with each of the other clusters (cluster I, 7.5 months; cluster II, 55.7 months; cluster III, 17.9 months; cluster IV, 27.9 months; cluster V, 21.0 months) and significantly increased risk of death compared with patients in the other clusters (cluster II: hazard ratio [HR], 4.95; 95% CI, 1.50-16.41;<i>P</i> = .009; cluster III: HR, 4.75; 95% CI, 1.49-15.12;<i>P</i> = .008; cluster IV: HR, 6.38; 95% CI, 1.76-23.09;<i>P</i> = .005; cluster V: HR, 5.42; 95% CI, 1.63-17.98;<i>P</i> = .006). The genetic profiles of cluster I were characterized by a high detection rate of<i>CDK4</i>(9 of 9 [100%]),<i>TP53</i>(8 of 9 [88.9%]),<i>MET</i>(7 of 9 [77.8%]), and<i>CDKN2A</i>(7 of 9 [77.8%]). For those with<i>EGFR</i>variants, coalterations with<i>CDK4</i>(HR, 2.02; 95% CI, 1.03-3.96;<i>P</i> = .04),<i>CDK6</i>(HR, 2.52; 95% CI, 1.32-4.83;<i>P</i> = .005), and<i>MYC</i>(HR, 2.24; 95% CI, 1.21-4.15;<i>P</i> = .01) were associated with poor outcomes. <h3>Conclusions and Relevance</h3> Patients with a diagnosis of lung adenocarcinoma and CNS metastases experienced heterogeneous survival outcomes based on genetic profiling in CSF. These data suggest that CSF might facilitate risk stratifying CNS metastases into appropriate outcomes and provide reference for further clinical study.